Gene · 3738
KCNA3: potassium voltage-gated channel subfamily A member 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KCNA3: potassium voltage-gated channel subfamily A member 3. Genes, record 3738. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3738
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P22001 | Potassium voltage-gated channel subfamily A member 3 | 575 | 16 | Ensembl, GeneID, HGNC |
Source UniProt
Patents28
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58778 | P22001 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 8853 | P22001 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2190 | P22001 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2190 | P22001 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 8853 | P22001 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 30217 | P22001 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 30217 | P22001 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 30217 | P22001 | Espacenet |
| US 11597763 B2 | 2023-03-07 | 1 | P22001 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 65836 | P22001 | Espacenet |
1 to 10 of 28
See all 28 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMIFAMPRIDINE | CHEMBL354077 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| AMIFAMPRIDINE PHOSPHATE | CHEMBL3301611 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| DALFAMPRIDINE | CHEMBL284348 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE | CHEMBL821 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| GUANIDINE HYDROCHLORIDE | CHEMBL1200728 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| NERISPIRDINE | CHEMBL2107762 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
| TEDISAMIL | CHEMBL113461 | Voltage-gated potassium channel blocker | BLOCKER | ChEMBL |
Trials86
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07532460 | DALFAMPRIDINE | ClinicalTrials.gov | ||
| NCT07185347 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT07171203 | DALFAMPRIDINE | PHASE1 | ClinicalTrials.gov | |
| NCT06853015 | DALFAMPRIDINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT06751784 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06596434 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06333171 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06294821 | DALFAMPRIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT06136728 | DALFAMPRIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05919407 | AMIFAMPRIDINE | PHASE3 | ClinicalTrials.gov |
1 to 10 of 86
See all 86 trialsNIH grants1,028
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KCNA3 papers | Newest fiscal year |
|---|---|---|---|
| R01NS041435 | Mechanisms by which effector T cells modulate endogenous remyelination | 12 | 2025 |
| T32DC000044 | Chemosensory Training Program (CTP) | 12 | 2025 |
| R01DC001919 | Expression of Ion Channels in the Auditory System | 6 | 2025 |
| P30AR070549 | Cincinnati Rheumatic Diseases Resource Center | 4 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 4 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 4 | 2025 |
| U10AA008401 | Collaborative Study on the Genetics of Alcoholism (COGA). | 4 | 2025 |
| P30ES019776 | HERCULES: Exposome Research Center | 3 | 2025 |
| R01AG075820 | Neuron and microglia-specific proteomic signatures of ERK mediated mechanisms of Alzheimer's disease. | 3 | 2025 |
| R01GM030376 | The Electrophysiological Studies of Voltage Gated Channels | 3 | 2025 |
1 to 10 of 1,028Source NIH's project files
See all 1,028 nih grantsPapers2,009
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Potassium channels as an ionic checkpoint in tumor immunity. | Front Pharmacol | 2026 | 42787526 | PubTator, text mining | PubMed |
| Piezo1 agonists are potent off-target inhibitors of the Kv1.3 channel via gating modification. | Mol Pharmacol | 2026 | 42691696 | PubTator, text mining | PubMed |
| Nanobody regulation of C-type inactivation in Kv1.3 channels. | Nat Commun | 2026 | 42680746 | PubTator, text mining | PubMed |
| KCNA3 Gene Polymorphism Affects the Efficacy and Plasma Concentration of Perampanel in Patients With Refractory Epilepsy. | Ther Drug Monit | 2026 | 42593405 | PubTator, text mining | PubMed |
| Psoriasis-Obesity-Related Gene COX7C Promotes Keratinocyte Proliferation and Positively Regulates Inflammatory Responses in Psoriasis. | J Cell Mol Med | 2026 | 42487278 | PubTator, text mining | PubMed |
| Comparative Interactome Analysis Reveals Architectural Principles Governing K+ Channel Function in Cancer. | Int J Mol Sci | 2026 | 42450133 | PubTator, text mining | PubMed |
| Integrated Screening Cascades for Ion-Channel Drug Discovery: Linking Structure, Electrophysiology, Safety Pharmacology, and Human-Relevant Models. | Int J Mol Sci | 2026 | 42450047 | PubTator, text mining | PubMed |
| Identification and validation of aging-related genes in patients with multiple myeloma. | Oncol Lett | 2026 | 42433653 | PubTator, text mining | PubMed |
| Kv1.3 modulates macrophage M2 polarization via the STAT3 pathway: A novel mechanism and therapeutic target for steroid-resistant asthma. | Transl Res | 2026 | 42341914 | PubTator, text mining | PubMed |
| Adaptor-mediated interaction between Kv1.3 and Nedd4-2 E3 ubiquitin ligase. | Commun Biol | 2026 | 42337377 | PubTator, text mining | PubMed |
1 to 10 of 2,009
See all 2,009 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3738
GET https://conductscience.org/api/genes/v1/3738/patents?page=2